Health TrialsbyHealthPanel

Sleep Duration and Cardiovascular Health

ConditionsSleepCardiovascular Risk Factor
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-65
SponsorOregon Health and Science University

About this trial

This is a cross-sectional study with an optional intervention that will examine how extreme sleep durations relate to cardiovascular health, physical activity, and sleep quality by studying three groups of participants: short sleepers (≤ 6 hrs), long sleepers (≥ 9 hrs), and average duration sleepers (7-8 hrs). The optional intervention asks participants to maintain an 8-hour per night regular sleep schedule for one week.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Men and women ages 25-65y

Lean and overweight (BMI 18.5-40 kg/m2)

No acute, chronic, or debilitating medical conditions

No prescription/non-prescription medications or drugs of abuse

Disqualifiers

Persons with any acute, chronic, or debilitating medical condition except pre-hypertension will be excluded.

Persons with any symptoms of acute or active illness (e.g. fever, leukocytosis) will be excluded.

Persons with a history of severe psychiatric illness or psychiatric disorders will be excluded.

Persons with a history of regular night/or rotating shift work in the past year, or who have traveled more than three time zones during the one month prior to the study will be excluded.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Regularized Sleep Schedule

    Behavioral

    Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.

Treatment groups

24 Participants
are divided into 3 treatment groups
Group A: Short SleepersExperimental treatment 1 intervention
Group B: Long SleepersExperimental treatment 1 intervention
Group C: Average Duration SleepersExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Vascular Endothelial Function

Investigators will measure endothelial function as flow-mediated dilation.

Time frame
2 weeks
2

Cardiovascular Risk

Investigators will measure cardiovascular risk as carotid intima-media thickness (IMT).

Time frame
2 weeks
3

Coronary Atherosclerotic Burden

Investigators may measure coronary atherosclerotic measure from a computerized tomography (CT) scan. This measure is optional for participants. The scan will be used to calculate coronary artery calcium score (CAC score and/or Agatston score). The CAC score indicates risk of future coronary artery events. A CAC score of 0 indicates absence of coronary artery calcification. A score of 0 is very low risk, and risk increases with increasing numbers (e.g. 100-300 is increased risk, \>300 is very high risk). Higher scores may indicate higher risk of future coronary events. The Agatston score is also an atherosclerotic measure that may indicate risk of future coronary artery events. Agatston also goes up from 1 on a linear scale (e.g. 1-100 is discreet atherosclerosis, up to 400 is moderate, \>400 is severe).

Time frame
2 weeks
4

Heart rate

Heart rate will be measured as beats per minute while participants are in a supine position.

Time frame
2 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Oregon Health and Science University

Lead sponsor

Source ClinicalTrials.gov
Apply now